Multiple sclerosis (MS) is an autoimmune disease in which immune cells attack and destroy the myelin sheath, a fatty tissue which insulates neurons in the brain and spinal cord and which helps nerve fibers conduct electrical impulses. When the myelin is destroyed, nerve messages are sent slower and less efficiently. Scar tissue then forms over the affected areas, disrupting nerve communication. MS is the most common neurological cause of debilitation in young people in the U.S. and worldwide. MultiCell’s most advanced therapeutic, MCT-125, is targeted at one of the most common symptoms of MS, fatigue, occurring in approximately 70% of MS patients. MultiCell is developing MCT-175, a immunoglobulin-peptide (Ig-Peptide) therapeutic, that specifically targets autoaggressive T-Cells which attack the myelin sheath of neurons. MCT-175 is currently in preclinical development for the treatment of relapsing-remitting MS.